Novartis’s Evolving R&D: An Interview With CMO Narasimhan At J.P. Morgan
Executive Summary
Novartis is under pressure to deliver new drugs in areas like oncology, cardiovascular disease and dermatology, where it is making significant investments. Chief Medical Officer Vasant Narasimhan talked about the company’s strategy in these areas and others, the company’s recent R&D reorganization and business development in an interview during the J.P. Morgan Healthcare Conference.
You may also be interested in...
Pharmas Pursue Tech Deals To Speed Drug Development, Measure Outcomes
Deals for technology platforms allow more of a multiple-shots-on-goal approach as opposed to taking a risk with one or two candidates.
In Novartis, Conatus Lands Experienced, Deep-Pocketed NASH Partner
Biotech gets $50m up front, up to $650m in milestones, significant royalties and the option to co-promote emricasan in NASH in the US. Novartis also may combine the caspase inhibitor with its Phase II FXR agonist.
Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity
New treatments for atopic dermatitis – including the first biologic medicine for the disease – could launch next year, fueling substantial growth in a therapy area where there have been few advances. Payers, however, will be keeping an eye on the cost.